Skip to Content

Fluoxymesterone Dosage

Applies to the following strength(s): 2 mg ; 5 mg ; 10 mg

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Hypogonadism - Male

-5 to 20 mg orally per day
-Usually preferable to start therapy at a higher level within the range (e.g., 10 mg) with subsequent adjustment as required.

-This drug may be given as a single dose or in divided doses.
-Dosage and duration of therapy will depend on age, sex, diagnosis, patient response to treatment, and appearance of adverse effects.

Uses: This drug is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.

-Primary hypogonadism (congenital or acquired)
-Hypogonadotropic hypogonadism (congenital or acquired)
-Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy
-Idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation

Usual Adult Dose for Breast Cancer-Palliative

Palliation of Inoperable Mammary Cancer:
-10 to 40 mg orally per day in divided doses for 3 months or more

Palliation of Advanced Mammary Carcinoma:
-Hormone therapy is adjunctive to and not a replacement for conventional therapy; therapy duration will depend on the response of the condition and the appearance of adverse reactions.

-Androgen therapy appears to occasionally accelerate the disease; patients should be followed closely.
-This treatment has been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.

Use: Secondary treatment in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal.

Usual Pediatric Dose for Delayed Puberty - Male

2.5 to 20 mg orally per day; generally in the lower range of 2.5 to 10 mg orally per day, taken in one single dose or in divided doses for a limited duration (e.g., 4 to 6 months).

-Various dosage regimens have been used: some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance level; other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty.
-The chronological and skeletal ages should be taken into consideration in determining the initial dose and when adjusting the dose.
-Brief treatment with conservative doses may occasionally be justified in these male patients if they do not respond to psychological support.
-Patients and parents should be advised of the potential adverse effect on bone maturation prior to treatment.
-Hand and wrist x-rays to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers.

Use: Stimulate puberty in adolescent males with clearly delayed puberty

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Dosage adjustments will depend on age, sex, diagnosis, patient response to treatment, and appearance of adverse effects.


Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule III


Data not available

Other Comments

Storage requirements:
-This drug should be dispensed in a tight, light-resistant container.

-If one of the conditions indicated for this drug treatment occurs prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics.
-Prolonged androgen treatment will be required to maintain sexual characteristics in males who develop testosterone deficiency after puberty.
-Adolescent male patients selected to receive this treatment usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date.
-This drug has not been shown to be safe and effective for the enhancement of athletic performance.

-Cardiovascular: Serum cholesterol levels
-Endocrine: Virilization signs
-Hematologic: Hemoglobin and hematocrit
-Hepatic: Liver function tests
-Metabolic: Urine and serum calcium levels
-Pediatric Patients: Wrist and hand x-rays (every six months)